Herpevac Trial for Women

Purpose: To assess the efficacy and safety of an experimental vaccine in the prevention of herpes simplex virus type-2 (HSV-2). Two late-stage (Phase III) trials of this vaccine have already been completed. Half of the participants will recieve the experimental herpes vaccine and half will receive a hepatitis A vaccine.

Study Visits and Procedures: Participants are screened for herpes. Only women negative for HSV-1 and HSV-2 will be eligible to participate. Eligible volunteers will be asked to come to the clinic for a total of 8 visitis over approximately 20 months. Volunteers may have additional visits if they have a suspected herpes infection during the trial.

For more information see: http://www.niaid.nih.gov/dmid/stds/herpevac/

Antigenics Phase 1 Vaccine Trial for HSV-2 Seropositive Persons

Purpose: The overall aim of the study is to determine the safety and immune response of an experimental therapeutic herpes vaccine (AG-707) compared to placebo in HSV-2 seropositive patients. The study is a Phase 1, randomized, double-blind trial.

Study Visits and Procedures: HSV-2 positive volunteers will be asked to come to the clinic for screening. Eligible participants will be asked to come to the clinic for a total of 13 visits over the course of 28 weeks.